Literature DB >> 27427873

Virologic and immunologic aspects of HIV-hepatitis C virus coinfection.

Kara W Chew1, Debika Bhattacharya.   

Abstract

HIV/hepatitis C virus (HCV) coinfection is estimated to affect 2 million individuals globally. The acceleration of HCV-associated complications, particularly hepatic fibrosis, because of HIV coinfection has been well established, whereas the impact of HCV on HIV progression remains unclear. In this review, we summarize the current evidence on the impact of coinfection on the transmission and clinical progression of each infection. We focus on the virological and immunological alterations that contribute to HIV and HCV pathogenesis in coinfection and also review the disease-modifying effects of antiretroviral therapy as they pertain to HCV.

Entities:  

Mesh:

Year:  2016        PMID: 27427873      PMCID: PMC6039386          DOI: 10.1097/QAD.0000000000001203

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  119 in total

1.  Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.

Authors:  Vivek Jain; Wendy Hartogensis; Peter Bacchetti; Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Lorrie Epling; Tzong-Hae Lee; Michael P Busch; Joseph M McCune; Christopher D Pilcher; Frederick M Hecht; Steven G Deeks
Journal:  J Infect Dis       Date:  2013-07-12       Impact factor: 5.226

2.  Determinants of the quantity of hepatitis C virus RNA.

Authors:  D L Thomas; J Astemborski; D Vlahov; S A Strathdee; S C Ray; K E Nelson; N Galai; K R Nolt; O Laeyendecker; J A Todd
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

3.  Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells.

Authors:  Yong-Han Paik; Robert F Schwabe; Ramón Bataller; Maria P Russo; Christian Jobin; David A Brenner
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

4.  Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.

Authors:  Jürgen K Rockstroh; Amanda Mocroft; Vincent Soriano; Cristina Tural; Marcello H Losso; Andrzej Horban; Ole Kirk; Andrew Phillips; Bruno Ledergerber; Jens Lundgren
Journal:  J Infect Dis       Date:  2005-08-11       Impact factor: 5.226

5.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

6.  Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects.

Authors:  Raymond T Chung; Scott R Evans; Yijun Yang; Dickens Theodore; Hernan Valdez; Rebecca Clark; Cecilia Shikuma; Thomas Nevin; Kenneth E Sherman
Journal:  AIDS       Date:  2002-09-27       Impact factor: 4.177

7.  Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes.

Authors:  Anuradha Balasubramanian; Ramesh K Ganju; Jerome E Groopman
Journal:  J Biol Chem       Date:  2003-06-24       Impact factor: 5.157

8.  HCV/HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus?

Authors:  Eugènia Mariné-Barjoan; Alain Berrébi; Valérie Giordanengo; Sébastien Fournier Favre; Hervé Haas; Michel Moreigne; Jacques Izopet; Joelle Tricoire; Albert Tran; Christian Pradier; André Bongain
Journal:  AIDS       Date:  2007-08-20       Impact factor: 4.177

9.  Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption.

Authors:  Patrick Marcellin; Françoise Pequignot; Elisabeth Delarocque-Astagneau; Jean-Pierre Zarski; Nathalie Ganne; Patrick Hillon; Denise Antona; Martine Bovet; Murielle Mechain; Tarik Asselah; Jean-Claude Desenclos; Eric Jougla
Journal:  J Hepatol       Date:  2007-11-20       Impact factor: 25.083

10.  IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.

Authors:  Thomas Reiberger; Judith H Aberle; Michael Kundi; Norbert Kohrgruber; Armin Rieger; Alfred Gangl; Heidemarie Holzmann; Markus Peck-Radosavljevic
Journal:  Antivir Ther       Date:  2008
View more
  10 in total

Review 1.  Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era.

Authors:  Eric G Meissner
Journal:  Curr Opin Gastroenterol       Date:  2017-05       Impact factor: 3.287

2.  Decreased Activated CD4+ T Cell Repertoire Diversity After Antiretroviral Therapy in HIV-1/HCV Coinfection Correlates with CD4+ T Cell Recovery.

Authors:  Nicole E Skinner; Candelaria Vergara; Ramy El-Diwany; Harry Paul; Alyza Skaist; Sarah J Wheelan; David L Thomas; Stuart C Ray; Ashwin Balagopal; Justin R Bailey
Journal:  Viral Immunol       Date:  2021-10-21       Impact factor: 2.175

Review 3.  A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection.

Authors:  Samaa T Gobran; Petronela Ancuta; Naglaa H Shoukry
Journal:  Front Immunol       Date:  2021-08-12       Impact factor: 7.561

4.  A spotlight on HCV and SARS-CoV-2 co-infection and brain function.

Authors:  Kate Shirley; Jennifer M Loftis
Journal:  Pharmacol Biochem Behav       Date:  2022-05-10       Impact factor: 3.697

Review 5.  Oncogenic Effects of HIV-1 Proteins, Mechanisms Behind.

Authors:  Maria Isaguliants; Ekaterina Bayurova; Darya Avdoshina; Alla Kondrashova; Francesca Chiodi; Joel M Palefsky
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

Review 6.  Co-Infection and Cancer: Host-Pathogen Interaction between Dendritic Cells and HIV-1, HTLV-1, and Other Oncogenic Viruses.

Authors:  Tania H Mulherkar; Daniel Joseph Gómez; Grace Sandel; Pooja Jain
Journal:  Viruses       Date:  2022-09-14       Impact factor: 5.818

7.  Hepatitis B and C infections in HIV-1 patients on combination antiretroviral therapy (cART) in Ghana: implications for immunologic recovery, clinical response to treatment, and hepatotoxicity.

Authors:  Theophilus Benjamin Kwofie; Daniel Adigbli; James Osei-Yeboah; Emmanuel Ativi; Sylvester Yao Lokpo
Journal:  Heliyon       Date:  2021-05-28

8.  The factors associated with natural disease progression from HIV to AIDS in the absence of ART, a propensity score matching analysis.

Authors:  X C Jia; Z H Xia; N Shi; Y P Wang; Z X Luo; Y L Yang; X Z Shi
Journal:  Epidemiol Infect       Date:  2020-02-24       Impact factor: 2.451

Review 9.  Advances in Continuous Microfluidics-Based Technologies for the Study of HIV Infection.

Authors:  Joëlle Eid; Marylène Mougel; Marius Socol
Journal:  Viruses       Date:  2020-09-04       Impact factor: 5.048

10.  Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV.

Authors:  Giulia Morsica; Laura Galli; Emanuela Messina; Antonella Castagna; Sabrina Bagaglio; Stefania Salpietro; Della Torre Liviana; Caterina Uberti-Foppa; Hamid Hasson
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.